Retatrutide
Experimental triple agonist hitting GLP-1, GIP, and glucagon receptors. The largest weight loss ever published for an obesity drug. Not approved anywhere.
Tirzepatide
FDA-approved dual GLP-1/GIP agonist, sold as Mounjaro and Zepbound. The most effective weight-loss medication you can legally obtain.
Side-by-Side Comparison
Not approved by any regulator. The only legitimate access is a clinical trial. Vials sold online are unregulated material with no verified identity, purity, or dose. This is the dimension that decides the comparison for almost everyone.
FDA-approved and widely prescribed. Available as branded Mounjaro and Zepbound, and through telehealth providers.
Phase 2 (n=338), 12mg weekly, published in NEJM. Phase 3 TRIUMPH-1 reported up to 30.3% over 80 weeks, so far only via press release.
SURMOUNT-1 (n=2,539), 15mg weekly, published in full. About 9 in 10 participants lost weight.
GLP-1 and GIP reduce how much you eat; glucagon increases how much you burn at rest and pushes the liver to burn stored fat. Attacking both sides of the equation is the leading explanation for the larger numbers.
GLP-1 and GIP together. No glucagon component, so the effect comes almost entirely from reduced intake rather than increased expenditure.
The 48-week phase 2 is peer-reviewed and well designed. The larger phase 3 results are so far sponsor press releases and conference talks, so the methods and safety tables cannot be independently checked yet.
Multiple large phase 3 trials published in full, plus years of real-world use and outcome data in sleep apnea, MASH, and type 2 diabetes.
Longest published trials run 48 to 80 weeks. The glucagon component is new to this drug class and is exactly the kind of addition that can surprise you at scale.
Approved since 2022, with millions of patient-years of exposure and post-marketing surveillance.
Any price you are quoted is for unregulated gray-market material, not the trial drug.
Varies widely by insurance coverage, manufacturer savings programs, and whether you use branded or a telehealth provider.
Nausea, vomiting, diarrhea, constipation, mostly during dose escalation. Dose-dependent heart rate increases were observed. Blood sugar needs watching because of the glucagon activity.
Same gastrointestinal profile, well characterized across large trials and real-world use. Manageable with slow escalation for most people.
Eli Lilly has said it plans to file for US approval in Q1 2027. Standard review would put a decision in late 2027 or 2028.
Approved for type 2 diabetes (2022), obesity (2023), and obstructive sleep apnea in adults with obesity (2024).
On paper this looks like a close race. In practice it is not a race at all, because only one of these is a real option.
**Tirzepatide** is the answer for essentially everyone reading this. It is approved, it is prescribable, it has multiple fully published phase 3 trials, and it has years of real-world safety data. Roughly 21% average weight loss is an extraordinary result that no drug could deliver five years ago.
**Retatrutide** genuinely does produce larger numbers, around 24% at 48 weeks in phase 2 and reportedly up to 30% in phase 3. The mechanism for why is sound: adding glucagon activity raises energy expenditure rather than only suppressing appetite. It is a legitimately exciting drug.
But it is not available, and the gap between "impressive trial results" and "something you can take" is the whole comparison. Anything sold online as retatrutide today is unregulated material of unverified identity and dose, manufactured by someone accountable to no one. You would be trading a proven, supervised, approved medication for a mystery vial in exchange for a difference of a few percentage points that may not even replicate outside a trial.
If retatrutide is approved in 2027 or 2028, revisit this. Until then the honest recommendation is tirzepatide, prescribed and monitored.
Which Is Right for You?
- You qualify for and can enrol in a TRIUMPH clinical trial
- You are researching what the obesity drug landscape looks like in 2027 and beyond
- You have not responded adequately to tirzepatide and your doctor is exploring trial options
- You want the most effective weight-loss medication you can legally obtain
- You want a drug with published phase 3 data and years of real-world safety monitoring
- You want prescriber supervision, a verified supply chain, and a known dose
- You also have type 2 diabetes or obstructive sleep apnea, which it is separately approved to treat
- You want any chance of insurance coverage
Important Note
This comparison is for educational purposes only and should not replace medical advice. The best medication for you depends on your individual health profile, medical history, and personal circumstances. Always consult with a healthcare provider who can evaluate your specific situation before starting any medication.
Frequently Asked Questions
Is retatrutide better than tirzepatide?
On trial weight loss alone, the numbers are higher: about 24% at 48 weeks for retatrutide in phase 2 versus about 21% at 72 weeks for tirzepatide. But these are separate trials with different populations and durations, not a head-to-head comparison, so the gap is suggestive rather than proven. And "better" has to include availability: tirzepatide is an approved medicine you can get with a prescription, and retatrutide is not approved anywhere.
Can I buy retatrutide instead of tirzepatide?
Not legally, and not the real thing. Retatrutide is not approved by any regulator, so there is no pharmacy supply chain for it. Material sold online has no verified identity, purity, or dose accuracy, and nobody is checking. You would be giving up a supervised, approved medication with years of safety data for an unverified vial.
Why does retatrutide cause more weight loss?
It adds a third target, the glucagon receptor, on top of the GLP-1 and GIP receptors tirzepatide hits. GLP-1 and GIP mainly reduce how much you eat. Glucagon increases how many calories you burn at rest and prompts the liver to burn stored fat. Working both sides of the equation is the leading explanation for the larger effect.
When will retatrutide be approved?
Eli Lilly has said it plans to submit retatrutide for US approval in the first quarter of 2027. A standard review would put a possible decision in late 2027 or 2028, assuming the submission goes smoothly. Any specific date quoted before then is speculation.
Should I wait for retatrutide?
Generally no. Approval is at least a couple of years away and is not guaranteed, and the health benefits of losing weight now compound over time. Starting tirzepatide today and switching later if something clearly better arrives is almost always the better plan than waiting for a drug that does not exist yet.